UNITEDHEALTH GROUP INC quarterly report, Q2 FY2022

Full document

UnitedHealth Group Inc. — Q2 2022 Form 10-Q

Reporting period: Three and six months ended June 30, 2022; filed August 3, 2022. Results are compared with the same periods in 2021. UnitedHealth Group operates UnitedHealthcare and Optum, with reportable segments UnitedHealthcare, Optum Health, Optum Insight and Optum Rx.

Financial performance

  • Q2 revenue: $80.3 billion, up 13% year over year. Premiums rose 14%, products 13% and services 9%; investment and other income declined 47% to $295 million.
  • Q2 earnings: Operating earnings were $7.1 billion, up 19%; net earnings attributable to common shareholders were $5.1 billion, up 19%. Diluted EPS was $5.34, up 20% from $4.46.
  • Q2 margins: Medical care ratio (MCR) was 81.5%, down 1.3 percentage points; operating margin was 8.9%, up 0.5 points; net earnings margin was 6.3%, up 0.3 points.
  • First-half results: Revenue was $160.5 billion, up 13%; operating earnings were $14.1 billion, up 11%; net earnings attributable to common shareholders were $10.1 billion, up 11%; diluted EPS was $10.61, up 11%. MCR was 81.8% versus 81.9%; operating margin was 8.8% versus 9.0%.
  • Segment performance, Q2: UnitedHealthcare revenue grew 12% and operating earnings 24%; Optum revenue grew 18% and operating earnings 14%. Optum Health revenue rose 32%, Optum Insight 11% and Optum Rx 10%.
  • Cash flow: First-half operating cash flow was $12.2 billion, versus $11.5 billion. Capital expenditures were $1.2 billion; operating cash flow less capital expenditures was approximately $11.0 billion. Cash and cash equivalents ended at $24.6 billion, including $1.7 billion available for general corporate use.
  • Liquidity and debt: Current assets were $68.4 billion and current liabilities $88.7 billion. Long-term debt was $45.8 billion, with $5.6 billion of short-term borrowings and current debt maturities. The company issued $6.0 billion of senior notes in May. Its credit-facility debt-to-debt-plus-shareholders’ equity ratio was approximately 37%, below the 60% covenant ceiling.
  • Capital returns: First-half share repurchases totaled $5.0 billion and dividends paid were $2.9 billion. In June, the board raised the annualized dividend rate to $6.60 per share from $5.80.

Material changes and management commentary

  • Revenue growth reflected increased enrollment in Medicare Advantage, Medicaid and commercial offerings, pricing trends, and growth across Optum. UnitedHealthcare served 1.6 million more people than a year earlier, mainly through community and senior programs.
  • Q2 MCR improvement reflected COVID-19 effects and business mix. For the first half, favorable COVID-19 effects were partly offset by business mix and less favorable prior-year reserve development than in 2021.
  • Management said care was near normal baseline levels overall in the first half, but patterns remained uneven. Deferred care could return, potentially with higher acuity, and COVID-19 trends may affect costs, utilization, risk-adjustment revenue and reserve estimates.
  • Cash flow rose year over year, while acquisition spending increased to $7.2 billion from $4.6 billion and repurchases increased to $5.0 billion from $2.9 billion.
  • During the first half, the company completed acquisitions for total consideration of $8.1 billion. Acquired entities’ contribution to revenue and earnings through June 30 was not material; purchase-price allocations remained preliminary.

Outlook, risks and contingencies

  • The filing provides no specific quantitative earnings or revenue guidance. Management stated that it believes capital resources are sufficient for short- and long-term liquidity needs.
  • Pending acquisitions, notably Change Healthcare and LHC Group, were subject to regulatory approval and other customary closing conditions. Anticipated capital required was approximately $14 billion, excluding disposition proceeds and repayment of acquired debt.
  • Legal and regulatory matters include government reviews and audits, including Medicare risk-adjustment data validation audits. A DOJ False Claims Act case alleges improper Medicare risk-adjustment submissions; the company said it could not reasonably estimate the outcome. Losses from certain legal and regulatory matters may be difficult to estimate.
  • Interest-rate increases drove substantial unrealized losses on available-for-sale debt securities: $2.843 billion gross at June 30, 2022. The company attributed the losses to rates rather than credit deterioration, said it did not intend to sell the affected securities, and considered the losses temporary.
  • Key stated risks include pandemic-related uncertainty, medical-cost estimation and pricing, healthcare regulation and government-program payments, litigation and audits, cybersecurity and privacy, acquisition execution, competition, credit ratings, and investment performance. The company reported no material changes to the risk factors in its 2021 10-K.

Important facts for investors to verify

  • Whether medical utilization, deferred care and COVID-19 effects alter MCR, medical-cost reserves or risk-adjustment revenue in subsequent periods.
  • Enrollment, margins and growth drivers across UnitedHealthcare and the four reportable segments, including the durability of Optum Health growth.
  • Financing, regulatory approvals, closing conditions and expected benefits for the Change Healthcare and LHC Group transactions.
  • Developments in Medicare risk-adjustment audits and the DOJ litigation, for which the filing provides no clear loss estimate.
  • Debt, available corporate cash and capital-return plans alongside acquisition funding needs.